Key result
Cardiomyoplasty, including dynamic and emerging cellular approaches, remains a potential biological bridge to heart transplantation and an alternative surgical treatment for severe cardiomyopathies.
Population
Patients with end-stage heart failure (CHF)
Design
Editorial
Authors
Loading...
Cardiomyoplasty, both dynamic and cellular, remains a topic of interest for end-stage heart failure, potentially serving as a bridge to transplantation or a platform for regenerative cardiology.
Cardiomyoplasty, both dynamic and cellular, remains a topic of interest for end-stage heart failure, potentially serving as a bridge to transplantation or a platform for regenerative cardiology.
Juan Carlos Chachques (2008) conducted a review in End-stage heart failure. Cardiomyoplasty was evaluated. Cardiomyoplasty, including dynamic and emerging cellular approaches, remains a potential biological bridge to heart transplantation and an alternative surgical treatment for severe cardiomyopathies.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: